Overview
ATYR market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ATYR price chart · 1M
- O
- 5.06
- H
- 5.06
- L
- 4.80
- C
- 4.80
- Vol
- 710.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $5.06
- Previous Close
- $4.81
- Day High
- $5.06
- Day Low
- $4.80
- 52 Week High
- $44.40
- 52 Week Low
- $4.08
- 7 Day Return
- -31.23%
- 30 Day Return
- -28.53%
- 90 Day Return
- -76.04%
- 1 Year Return
- -83.01%
- Daily Notional Volume
- $3.4K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$31.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -13,549.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.07 – $44.40 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $12M · P/B 1.14 · P/S 63.05.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Systemic Sclerosis Market to Exhibit Growth at a 3% CAGR During the Forecast Period (2026–2036) as Emerging Therapies Expand Treatment Opportunities | DelveInsightGlobenewswire Inc ·
8-K filing — aTYR PHARMA INC (ATYR)SEC EDGAR ·
aTyr Pharma Announces One-for-40 Reverse Stock SplitGlobenewswire Inc ·